Mesalazine

Mesalazine, the active ingredient in this product, is a 5-aminosalicylic acid (5-ASA) presented as a rectal formulation for rectal use. It reduces inflammation in the colon and is prescribed for ulcerative colitis and Crohn's disease with colonic involvement in patients who need local anti‑inflammatory therapy.

GNH USA supplies Mesalazine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine acts locally in the colon to control inflammatory bowel disease. - Ulcerative colitis: induces remission and reduces mucosal inflammation. - Crohn's disease (colonic involvement): controls colonic inflammation and helps maintain remission. - Maintenance therapy for ulcerative colitis: sustains remission after induction treatment.

Mesalazine may cause a range of adverse reactions, most of which are mild and related to its rectal administration.

Common Side Effects: - Rectal irritation or burning sensation. - Abdominal pain or cramping. - Nausea or mild headache. - Flatulence and loose stools.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling). - Blood in stool or severe colitis. - Hepatotoxicity or elevated liver enzymes. - Pancreatitis or Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: assess baseline and monitor periodically. - Hepatic function: check liver enzymes before and during treatment. - Severe ulcerative colitis: use with caution and monitor response closely. - Known hypersensitivity: avoid in patients with allergy to mesalazine or related compounds. - Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original package, protect from moisture and direct sunlight.

Mesalazine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: potentiation of anticoagulant effect, may raise INR. - Live vaccines: reduced efficacy, consider postponing vaccination.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened gastrointestinal irritation. - Oral contraceptives: possible reduction in hormonal effectiveness. - Lithium: potential for increased lithium serum levels.